Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: A 10-yr retrospective study

Critical Care Medicine

Volumn 38, Issue 10, 2010, Pages 1984-1990

  Chen, Shiuan Chih ^a,b   Chan, Khee Siang ^a,c   Chao, Wai Nang ^c   Wang, Po Hui ^a   Lin, Ding Bang ^a,b   Ueng, Kwo Chang ^a,b   Kuo, Sheng Hung ^a,d   Chen, Chun Chieh ^a,b   Lee, Meng Chih ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d Yuan Lin Kuo Hospital   (Taiwan)

Author keywords

Acute Physiology and Chronic Health Evaluation; intensive care; mortality; prognostic factor; Vibrio vulnificus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; MINOCYCLINE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; APACHE; ARTICLE; BULLOUS SKIN DISEASE; DEATH; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NECROTIZING FASCIITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN INFECTION; SOFT TISSUE INFECTION; VIBRIO VULNIFICUS INFECTION; COMPLICATION; CONFIDENCE INTERVAL; FASCIITIS, NECROTIZING; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FASCIITIS, NECROTIZING; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 77957220646     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181eeda2c     Document Type: Article

References (41)

1. Blake PA, Merson MH, Weaver RE, et al: Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979; 300:1-5
2. Klontz KC, Lieb S, Schreiber M, et al: Syndromes of Vibrio vulnificus infections: Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988; 109: 318-323
3. Levine WC, Griffin PM: Vibrio infections on the Gulf Coast: Results of first year of regional surveillance Gulf Coast Vibrio Working Group. J Infect Dis 1993; 167:479-483
4. Hsueh PR, Lin CY, Tang HJ, et al: Vibrio vulnificus in Taiwan. Emerg Infect Dis 2004; 10:1363-1368
5. Chuang YC, Young CD, Chen CW: Vibrio vulnificus infection. Scand J Infect Dis 1989; 21:721-726
6. Chuang YC, Yuan CY, Liu CY, et al: Vibrio vulnificus infection in Taiwan: Report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis 1992; 15: 271-276
7. Howard RJ, Bennett NT: Infections caused by halophilic marine Vibrio bacteria. Ann Surg 1993; 217:525-530
8. Hlady WG, Klontz KC: The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis 1996; 173:1176-1183
9. Liu JW, Lee IK, Tang HJ, et al: Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006; 166: 2117-2123
10. Chung PH, Chuang SK, Tsang T, et al: Cutaneous injury and Vibrio vulnificus infection. Emerg Infect Dis 2006; 12:1302-1303
11. Inoue Y, Ono T, Matsui T, et al: Epidemio-logical survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol 2008; 35:129-139
12. Johnston JM, Becker SF, McFarland LM: Vibrio vulnificus. Man and the sea. JAMA 1985; 253:2850-2853
13. Tsai YH, Hsu RW, Huang TJ, et al: Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am 2007; 89:631-636
14. Abbott SL, Janda JM, Johnson JA, et al: Vibrio and related organisms. In: Manual of clinical microbiology. Volume I. Ninth Edition. Murray PR, Baron EJ, Jorgensen JH, et al (Eds.) Washington, DC, ASM Press, 2007, pp 723-733
15. Guidelines for intensive care unit admission, discharge, and triage Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999; 27:633-638
16. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
17. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
18. Köstler W, Strohm PC, Sü dkamp NP: Acute compartment syndrome of the limb. Injury 2005; 36:992-998
19. Gourgiotis S, Villias C, Germanos S, et al: Acute limb compartment syndrome: A review. J Surg Educ 2007; 64:178-186
20. Youden WJ: An index for rating diagnostic tests. Cancer 1950; 3:32-35
21. Schisterman EF, Perkins NJ, Liu A, et al: Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples. Epidemiology 2005; 16:73-81
22. Howard RJ, Lieb S: Soft-tissue infections caused by halophilic marine Vibrios. Arch Surg 1988; 123:245-249
23. Penman AD, Lanier DC Jr, Avara WT 3rd, et al: Vibrio vulnificus wound infections from the Mississippi Gulf coastal waters: June to August 1993. South Med J 1995; 88:531-533
24. Chiang SR, Chuang YC: Vibrio vulnificus infection: Clinical manifestations, pathogene-sis, and antimicrobial therapy. J Microbiol Immunol Infect 2003; 36:81-88
25. Kuo YL, Shieh SJ, Chiu HY, et al: Necrotiz-ing fasciitis caused by Vibrio vulnificus: Epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis 2007; 26:785-792
26. Shapiro RL, Altekruse S, Hutwagner L, et al: The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis 1998; 178: 752-759
27. Meakins JL, Solomkin JS, Allo MD, et al: A proposed classification of intra-abdominal infections: Stratification of etiology and risk for future therapeutic trials. Arch Surg 1984; 119:1372-1378
28. Wong DT, Crofts SL, Gomez M, et al: Evaluation of predictive ability of APACHE II system and hospital outcome in Canadian intensive care unit patients. Crit Care Med 1995; 23:1177-1183
29. Hor LI, Chang TT, Wang ST: Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: Association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis 1999; 179:275-278
30. Powell JL, Strauss KA, Wiley C, et al: Inflammatory cytokine response to Vibrio vulnifi-cus elicited by peripheral blood mononuclear cells from chronic alcohol users is associated with biomarkers of cellular oxidative stress. Infect Immun 2003; 71:4212-4216
31. Kim HR, Rho HW, Jeong MH, et al: Hemo-lytic mechanism of cytolysin produced from Vibrio vulnificus. Life Sci 1993; 53:571-577
32. Biosca EG, Amaro C: Toxic and enzymatic activities of Vibrio vulnificus biotype 2 with respect to host specificity. Appl Environ Mi-crobiol 1996; 62:2331-2337
33. Park SD, Shon HS, Joh NJ: Vibrio vulnificus septicemia in Korea: Clinical and epidemio-logic findings in seventy patients. J Am Acad Dermatol 1991; 24:397-403
34. Halow KD, Harner RC, Fontenelle LJ: Primary skin infections secondary to Vibrio vulnificus: The role of operative intervention. J Am Coll Surg 1996; 183:329-334
35. Chuang YC, Ko WC, Wang ST, et al: Mino-cycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998; 42:1319-1322
36. Chuang YC, Liu JW, Ko WC, et al: In vitro synergism between cefotaxime and minocy-cline against Vibrio vulnificus. Antimicrob Agents Chemother 1997; 41:2214-2217
37. Bowdre JH, Hull JH, Cocchetto DM: Antibiotic efficacy against Vibrio vulnificus in the mouse: Superiority of tetracycline. J Pharmacol Exp Ther 1983; 225:595-598
38. Morris JG Jr, Tenney J: Antibiotic therapy for Vibrio vulnificus infection. JAMA 1985; 253: 1121-1122
39. Hsueh PR, Chang JC, Chang SC, et al: In vitro antimicrobial susceptibility of Vibrio vulnificus isolated in Taiwan. Eur J Clin Mi-crobiol Infect Dis 1995; 14:151-153
40. Tang HJ, Chang MC, Ko WC, et al: In vitro and in vivo activities of newer fluoroquino-lones against Vibrio vulnificus. Antimicrob Agents Chemother 2002; 46:3580-3584
41. Glas AS, Lijmer JG, Prins MH, et al: The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135